KAITLYN NEVILL: Open Payments
NPI 1740760784 · BRAZIL, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$598 in 28 payments from 9 companies in 2025. Trend: 2023 $1,193 · 2024 $1,545 · 2025 $598
Food & beverage: $566Education: $32
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics | 11 | $245 |
| ABBVIE INC. | 4 | $91 |
| Novo Nordisk Inc | 4 | $90 |
| Lilly USA, LLC | 3 | $55 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
| MERZ NORTH AMERICA, INC. | 1 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $20 |
| Exact Sciences Corporation | 1 | $17 |
Products named: Korlym, UBRELVY, MOUNJARO, Wegovy, AIRSUPRA, Xeomin, QULIPTA, Ozempic.
Industry payments across IN — which companies pay providers there.
